Chemomab (CMMB) CDO John Lawler details option and RSU holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Chemomab Therapeutics Ltd. Chief Development Officer John Lawler filed an initial Form 3 reporting his existing equity interests in the company. This filing does not show any new purchases or sales, only current holdings.
Lawler holds stock options over 12,500, 10,864 and 7,500 American Depositary Shares with exercise prices of $20.52, $5.68 and $2.20 per ADS, expiring in 2032, 2033 and 2034, respectively. Some of these options are already fully vested, while others vest in quarterly installments.
He also reports direct holdings of American Depositary Shares, including awards of RSUs granted in October 2024 and April 2025 that vest 25% on the first anniversary of grant and then in 12 quarterly installments of 6.25% until October 1, 2028 and April 10, 2029.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Lawler John
Role
Chief Development Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| holding | American Depositary Shares | -- | -- | -- |
| holding | American Depositary Shares | -- | -- | -- |
| holding | American Depositary Shares | -- | -- | -- |
Holdings After Transaction:
Stock option (right to buy American Depositary Shares) — 12,500 shares (Direct);
American Depositary Shares — 500 shares (Direct)
Footnotes (1)
- The American Depositary Shares reported in this row consist of RSUs that were granted to the Reporting Person by the Issuer on October 1, 2024 and vest and become exercisable according to following schedule: 25% on October 1, 2025, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on October 1, 2028. The American Depositary Shares reported in this row consist of RSUs that were granted to the Reporting Person by the Issuer on April 10, 2025 vest and become exercisable according to following schedule: 25% on April 10, 2026, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on April 10, 2029. The options reported in this row were granted to the Reporting Person by the Issuer on January 24, 2022, and are fully vested and exercisable as of the date of this report. The options reported in this row were granted to the Reporting Person by the Issuer on July 11, 2023, and vest and become exercisable according to following schedule: 25% on July 11, 2024, thereafter, in 12 equal quarterly installments of 6.25%, such that all options reported in this row will be exercisable on July 11, 2027. The options reported in this row were granted to the Reporting Person by the Issuer on February 8, 2024, and and are fully vested and exercisable as of the date of this report.
Key Figures
Option underlying shares: 12,500 ADS
Option underlying shares: 10,864 ADS
Option underlying shares: 7,500 ADS
+3 more
6 metrics
Option underlying shares
12,500 ADS
Exercise price $20.52; expiration January 24, 2032
Option underlying shares
10,864 ADS
Exercise price $5.68; expiration July 11, 2033
Option underlying shares
7,500 ADS
Exercise price $2.20; expiration February 8, 2034
RSU vesting end date
October 1, 2028
RSUs granted October 1, 2024 fully exercisable by this date
RSU vesting end date
April 10, 2029
RSUs granted April 10, 2025 fully exercisable by this date
Reported ADS holding
20,000 ADS
Direct American Depositary Share position reported as of transaction date
Key Terms
American Depositary Shares, RSUs, Stock option (right to buy American Depositary Shares), fully vested and exercisable, +1 more
5 terms
RSUs financial
"consist of RSUs that were granted to the Reporting Person"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
fully vested and exercisable financial
"are fully vested and exercisable as of the date of this report"
quarterly installments of 6.25% financial
"thereafter, in 12 equal quarterly installments of 6.25%"
FAQ
What does the Chemomab (CMMB) Form 3 for John Lawler show?
The Form 3 shows Chief Development Officer John Lawler’s existing equity holdings in Chemomab Therapeutics. It lists his stock options and American Depositary Share (ADS) positions, including RSU grants and vesting schedules, without reporting any new share purchases or sales.
How many Chemomab (CMMB) options does John Lawler report on Form 3?
John Lawler reports stock options over 12,500, 10,864 and 7,500 American Depositary Shares. These options carry exercise prices of $20.52, $5.68 and $2.20 per ADS and expire in 2032, 2033 and 2034, respectively, with a mix of fully vested and vesting tranches.
What are the key vesting terms for John Lawler’s Chemomab RSUs?
Lawler’s RSUs granted in October 2024 and April 2025 each vest 25% on the first anniversary of grant, then in 12 quarterly installments of 6.25%, so they become fully exercisable by October 1, 2028 and April 10, 2029, respectively.
What are the exercise prices of John Lawler’s Chemomab stock options?
Lawler’s reported stock options over American Depositary Shares have exercise prices of $20.52, $5.68 and $2.20 per ADS. Some of these options are already fully vested and exercisable, while others vest over time based on quarterly installment schedules.